Alltracel's six-month EBITDA climbs 64%

Irish drugmaker Alltracel Pharmaceuticals says that, for the six months ended June 30, 2007, its earnings before interest, taxes, depreciation and amortization were 592,000 euros ($820,732), up 64.4% on the year-earlier comparable period. The firm also saw its gross margin climb 4% to 40%, as revenue for the half year increased 6.3% to 10.1 million euros.

Commenting on the results, Alltracel chief executive Tony Richardson said: "the first half of 2007 has seen significant developments in trading profitability, scientific and commercial breakthroughs and significant M&A activity."

He added that, following the planned acquisition of Germany's Synpart AG (Marketletter September 3), Alltracel intends to combine its purchase with its existing Westone oral care division, and its m.doc wound-care operations in the newly formed organization, Synpart Limited.